Endotelix Diagnostics wins VentureKick Stage 3
Share this article
Endotelix Diagnostics Sàrl | Solution provider for Antiphospholipid Syndrome
In 2020, VentureKick allocated CHF 5 million to 80 Swiss startup projects.
Antiphospholipid Syndrome (APS) is one of the main causes of strokes in young people and triggers over 100’000 miscarriages per year in Europe. Entodelix‘ solution aims to provide a rapid and efficient diagnostic of APS as well as an adapted therapy response.